112 related articles for article (PubMed ID: 3643679)
1. Thermal inactivation of human immunodeficiency virus in lyophilised blood products evaluated by ID50 titrations.
Tersmette M; de Goede RE; Over J; de Jonge E; Radema H; Lucas CJ; Huisman HG; Miedema F
Vox Sang; 1986; 51(3):239-43. PubMed ID: 3643679
[TBL] [Abstract][Full Text] [Related]
2. Heat inactivation of human immunodeficiency virus in lyophilized anti-inhibitor coagulant complex (Autoplex).
Piszkiewicz D; Thomas W; Lieu M; Cabradilla CD; Andrews J; Kim J; Bourret E; McDougal JS; Cort SP
Thromb Res; 1986 Dec; 44(5):701-7. PubMed ID: 3492776
[No Abstract] [Full Text] [Related]
3. Heat inactivation of human immunodeficiency virus in solutions of antithrombin III.
Einarsson M; Perenius L; McDougal JS; Cort S
Transfusion; 1989 Feb; 29(2):148-52. PubMed ID: 2919425
[TBL] [Abstract][Full Text] [Related]
4. A strategy for testing established human plasma protein manufacturing procedures for their ability to inactivate or eliminate human immunodeficiency virus.
Hilfenhaus J; Geiger H; Lemp J; Hung CL
J Biol Stand; 1987 Jul; 15(3):251-63. PubMed ID: 3649341
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factor.
Mazurier C; de Romeuf C; Parquet-Gernez A; Jorieux S; Goudemand M
Vox Sang; 1987; 52(4):265-71. PubMed ID: 3114955
[TBL] [Abstract][Full Text] [Related]
6. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
[TBL] [Abstract][Full Text] [Related]
7. Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.
Piszkiewicz D; Bourret L; Lieu M; Hattley K; Thomas W; Cabradilla CD; Kingdon H; Menache D
Thromb Res; 1987 Jul; 47(2):235-41. PubMed ID: 3116716
[No Abstract] [Full Text] [Related]
8. Effect of heat treatment of lyophilised blood derivatives on infectivity of human immunodeficiency.
Lancet; 1986 May; 1(8492):1280-1. PubMed ID: 2872426
[No Abstract] [Full Text] [Related]
9. Heat sterilisation to inactivate AIDS virus in lyophilised factor VIII.
Margolis J; Li ZP
Aust N Z J Med; 1986 Jun; 16(3):413. PubMed ID: 3096270
[No Abstract] [Full Text] [Related]
10. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates.
Hart HF; Hart WG; Crossley J; Perrie AM; Wood DJ; John A; McOmish F
Vox Sang; 1994; 67(4):345-50. PubMed ID: 7701804
[TBL] [Abstract][Full Text] [Related]
11. Development and small-scale production of a severely heated factor VIII concentrate.
Knevelman A; de Wit HJ; Potstra P; vd Does JA
Vox Sang; 1994; 66(2):89-95. PubMed ID: 8184598
[TBL] [Abstract][Full Text] [Related]
12. Reduction of human immunodeficiency virus-infected cells from donor blood by leukocyte filtration.
Rawal BD; Busch MP; Endow R; Garcia-de-Lomas J; Perkins HA; Schwadron R; Vyas GN
Transfusion; 1989 Jun; 29(5):460-2. PubMed ID: 2734825
[TBL] [Abstract][Full Text] [Related]
13. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
14. Effect of monosaccharides during severe dry heat treatment of coagulation factor VIII concentrates.
Knevelman A; de Wit HJ; Griffin B; Hart H; McIntosh RV
Vox Sang; 1994; 66(2):96-103. PubMed ID: 8184599
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of a heat treated antihaemophilic cryoprecipitate.
Skjønsberg OH; Gravem K; Kierulf P; Godal HC
Thromb Res; 1987 Mar; 45(5):625-34. PubMed ID: 3109063
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of human T-cell lymphotropic virus, type III by heat, chemicals, and irradiation.
Quinnan GV; Wells MA; Wittek AE; Phelan MA; Mayner RE; Feinstone S; Purcell RH; Epstein JS
Transfusion; 1986; 26(5):481-3. PubMed ID: 3094204
[TBL] [Abstract][Full Text] [Related]
17. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
Roberts PL; Dunkerley C; McAuley A; Winkelman L
Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: the impact of heat treatment.
Ingerslev J; Bukh A; Wallevik K; Møller NP; Stenbjerg S
Thromb Res; 1987 Jul; 47(2):175-82. PubMed ID: 3116714
[TBL] [Abstract][Full Text] [Related]
19. [Transmission of the human immunodeficiency virus by a dry heat-treated Factor VIII concentrate?].
Weisser J
Klin Padiatr; 1988; 200(5):375-9. PubMed ID: 3141670
[TBL] [Abstract][Full Text] [Related]
20. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
